Structure Therapeutics Inc. American Depositary Shares (GPCR · NASDAQ)

GPCR · MARKET VIEW

Market view · as of Jun 22, 2026

Revenue (TTM)
$0
0.0% YoY
EPS (latest q)
$-0.35
vs $-0.35 est · in line
52-wk position
36.5%
-52.5% vs 52w high · +20.7% 1mo

Price (last ~year)

Structure Therapeutics (GPCR) is a clinical-stage biopharmaceutical company with a $3.16 billion market cap, reporting no revenue and a $76.2 million net loss for the quarter ended March 31, 2026. The company maintains $316.2 million in cash against $5.8 million in total debt. Shares closed at $44.51, up 20.7% over the past month, following recent shareholder meetings and director option grants.

Valuation

Market cap
$3.16B
P/B
2.19
EV/EBITDA
-13.46
Beta
-1.423
Analyst target
$104.59

Quality & returns

Operating margin
0.0%
Profit margin
0.0%
ROE
-15.0%
ROA
-11.6%

Price movement

Last
$44.51
1-month
+20.7%
3-month
-5.4%
RSI (14)
68
vs SMA200
-7.7%
52-wk position
36.5% -52.5% vs high

Quarterly trajectory

Revenue by quarter (oldest → newest)

QuarterRevenueOp incomeNet incomeEBITDA
2026-03-31$0$-89.6M$-76.2M$-74.8M
2025-12-31$0$24.0M$33.0M$33.6M
2025-09-30$0$-73.8M$-65.7M$-65.3M
2025-06-30$0$-70.5M$-61.7M$-61.2M

Recent news

Sources this view read

  • fundamentals Company overview & valuation (Alpha Vantage OVERVIEW)
  • filing Quarterly financial statements (Alpha Vantage INCOME/BALANCE/CASH)
  • earnings Reported earnings history (Alpha Vantage EARNINGS)
  • prices Adjusted daily prices (Alpha Vantage TIME_SERIES_DAILY_ADJUSTED)

Other snapshots